title: Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation.
abstract: BACKGROUND
  A prolonged treatment with oral anticoagulants has been claimed to reduce the incidence of newly diagnosed cancer in the long-term follow-up of patients with venous thromboembolism.
  
  
  OBJECTIVE
  In a multicenter prospective study we assessed the incidence of newly diagnosed clinically overt cancer in patients with a first episode of idiopathic venous thromboembolism (VTE) treated with oral anticoagulants for 3 months or 1 year.
  
  
  METHODS
  Consecutive patients with an idiopathic venous thromboembolism who had completed 3 months of oral anticoagulant therapy without having a recurrence, bleeding or newly diagnosed cancer were randomized to discontinue oral anticoagulant therapy or to continue it for nine additional months. Idiopathic venous thromboembolism was defined as thrombosis occurring in the absence of known cancer, known thrombophilia, or temporary risk factors for venous thromboembolism. All patients were followed up for at least 1 year after randomization.
  
  
  RESULTS
  A total of 429 patients, 265 patients with DVT and 164 with PE, were followed up for an average of 43.7 months after randomization. A newly diagnosed cancer occurred in 32 patients (7.5%), 13 (6.2%) of the 210 patients treated for 3 months and 19 (8.7%) of the 219 patients treated for 1 year (RR = 0.71, 95% confidence interval 0.36-1.41).
  
  
  CONCLUSIONS
  The incidence of newly diagnosed clinically overt cancer is not reduced in patients with idiopathic venous thromboembolism treated with 1-year anticoagulant treatment compared with patients treated for 3 months.
authors.affiliation: Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, Università di Perugia, Perugia, Italy.
authors.forename: M R
authors.initials: MR
authors.lastname: Taliani
authors.forename: G
authors.initials: G
authors.lastname: Agnelli
authors.forename: P
authors.initials: P
authors.lastname: Prandoni
authors.forename: C
authors.initials: C
authors.lastname: Becattini
authors.forename: M
authors.initials: M
authors.lastname: Moia
authors.forename: M
authors.initials: M
authors.lastname: Bazzan
authors.forename: W
authors.initials: W
authors.lastname: Ageno
authors.forename: C
authors.initials: C
authors.lastname: Tomasi
authors.forename: G
authors.initials: G
authors.lastname: Guazzaloca
authors.forename: G B
authors.initials: GB
authors.lastname: Ambrosio
authors.forename: A
authors.initials: A
authors.lastname: Bertoldi
authors.forename: R
authors.initials: R
authors.lastname: Salvi
authors.forename: R
authors.initials: R
authors.lastname: Poggio
authors.forename: M
authors.initials: M
authors.lastname: Silingardi
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D009369:Neoplasms / Q000139:chemically induced / Q000209:etiology*; D011655:Pulmonary Embolism / Q000150:complications / Q000188:drug therapy*; D012306:Risk; D013923:Thromboembolism / Q000150:complications / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants